For most people with hepatitis C, drugs are now available to prevent hepatitis C from becoming a chronic disease. An acute infection may clear on its own without treatment in about 25% of people. Since 2011, new treatments have been available for persons living with hepatitis C and have shown to cure 90% of persons with 8–12 weeks of oral therapy.
Below are links to several resources that can assist people in understanding hepatitis C and in managing their health.
Advocacy and support
Clinical trials
Drug assistance
- Abbvie/MAVYRET
- Genentech/Pegassist
- Gilead/Sovaldi
- Janssen/Olysio
- Pharmaceutical Company Patient Assistance and Cost-sharing Assistance Programs: Hepatitis
- Common Patient Assistance Program: Application and Companion Document
Information on how to apply for pharmaceutical assistance programs that offer medicines at little or no cost to eligible patients. - Wisconsin AIDS/HIV Drug Assistance Program
The Wisconsin AIDS/HIV Drug Assistance Program (ADAP) provides eligible HIV-infected persons access to HIV-related antiretroviral drugs and prophylactic medications. The ADAP drug formulary includes hepatitis C virus (HCV) medications for persons co-infected with HIV and HCV as well as vaccines for hepatitis A and B.
Assistance in paying for care
General and special interests
- Hepatitis C Infection - General Information (Multiple Languages)
- Hepatitis A, B, and C Summary Table (PDF)
- Hepatitis C in Wisconsin: Increase Among Young People Who Inject Drugs, P-02322 (PDF)
- American Liver Foundation
- Centers for Disease Control and Prevention (CDC) - Division of Viral Hepatitis
- CDC Hepatitis Publications and Information Resources
- Immunization Action Coalition
Last Revised: February 15, 2021
